The analysis also revealed a similar ADAM8 positivity rate (~ 30%) in all other non-TNBC breast cancer subtypes, including HR−/HER2+ (6/22 = 27.3%), HR+/HER2− (100/301 = 33.2%) and HR+/HER2+ (9/28 = 32.1%), that had not been examined previously. Here, ERBB2 is linked to breast cancer.